Seguridad de la inmunoterapia subcutánea con extractos tirosinados de ácaros de polvo doméstico en pacientes  con enfermedad alérgica

Molina-Sáenz, Mónica María; Villa-Arango, Ana María; Cardona-Villa, Ricardo

doi:10.29262/ram.v64i1.233

Cited by 4 publications

(3 citation statements)

References 46 publications

(48 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…That study showed that immunological potency inducing allergen-specific IgG4 antibody was the highest in aqueous HDM extract and the lowest in tyrosine-adsorbed HDM extract. Another previous study reported a very low incidence of SR (0.35%; 45 of 12,546 injections) during the conventional schedule of SCIT with tyrosine-adsorbed HDM extract in patients with allergic diseases 20. Therefore, in this study, we used a tyrosine-adsorbed HDM extract for UR-SCIT.…”

Section: Discussionmentioning

confidence: 98%

“…The severity and incidence of SR during SCIT are dependent on the potency of the allergen extract 12. We searched for a HDM preparation for SCIT with a relatively low allergenic potency and low incidence of SR but having reasonable evidence of clinical efficacy in patients with AD and AR 61420. A previous study compared the immunological potencies of 3 kinds of commercially available HDM extracts for SCIT (aluminum hydroxide-adsorbed HDM extract, tyrosine-adsorbed HDM extract, and aqueous HDM extract) in patients with allergic diseases 21.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Safety of Ultra-rush Schedule of Subcutaneous Allergen Immunotherapy With House Dust Mite Extract Conducted in an Outpatient Clinic in Patients With Atopic Dermatitis and Allergic Rhinitis

Lee

Kim

Shin

et al. 2019

Allergy Asthma Immunol Res

View full text Add to dashboard Cite

Purpose: Ultra-rush schedule of subcutaneous allergen immunotherapy (UR-SCIT) administering maximum maintenance dose of allergen extract within one day can save time and effort for allergen immunotherapy in patients with allergic disease. However, UR-SCIT is associated with an increased risk of systemic reaction (SR) and typically has been conducted in a hospital admission setting. To overcome disadvantages of UR-SCIT, we evaluated the safety of UR-SCIT conducted in an outpatient clinic in patients with atopic dermatitis (AD) and allergic rhinitis (AR). Methods: UR-SCIT was performed in 538 patients with AD and/or AR sensitized to house dust mite (HDM). A maximum maintenance dose of tyrosine-adsorbed HDM extract (1 mL of maintenance concentration) was divided into 4 increasing doses (0.1, 0.2, 0.3, and 0.4 mL) and administered to the patients by subcutaneous injection at 2-hour intervals for 8 hours in an outpatient clinic. SRs associated with UR-SCIT were classified according to the World Allergy Organization grading system. Results: SR was observed in 12 of 538 patients (2.2%) with AD and/or AR during UR-SCIT. The severity grades of the observed SRs were mild-to-moderate (grade 1 in 7 patients, grade 2 in 4 patients, and grade 3 in 1 patient). The scheduled 4 increasing doses of HDM extract could be administered in 535 of 538 patients (99.4%) except 3 patients who experienced SR before administration of the last scheduled dose. SR was observed within 2 hours in 11 patients after administration of the scheduled doses of HDM extract except one patient who experienced a grade 2 SR at 5.5 hours after administration of the last scheduled dose. Conclusions: UR-SCIT with tyrosine-adsorbed HDM extract conducted in an outpatient clinic was tolerable in patients with AD and AR. UR-SCIT can be a useful method to start a SCIT in patients with AD and AR.

show abstract

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 99%

Safety of Ultra-rush Schedule of Subcutaneous Allergen Immunotherapy With House Dust Mite Extract Conducted in an Outpatient Clinic in Patients With Atopic Dermatitis and Allergic Rhinitis

Lee

Kim

Shin

et al. 2019

Allergy Asthma Immunol Res

View full text Add to dashboard Cite

show abstract

“…10 A fi nal del seguimiento y 12546 dosis se registraron 45 reacciones adversas sistémicas (tasa de reacción 0.35 % por 100 inyecciones), para una tasa de incidencia de 5.8 % No se produjeron reacciones fatales. 11 Con el extracto de ácaros polimerizados, 622 pacientes tuvieron una tasa de reacción de 1.06 por 100 inyecciones, 93.1 % grados 1 y 2. 12 De acuerdo con estos tres estudios no hubo diferencias estadísticamente signifi cativas en la frecuencia o severidad de las reacciones entre estos dos extractos de ácaros modifi cados de inmunoterapia subcutánea (ITSC).…”

Section: Seguridadunclassified